RPL29

Large ribosomal subunit protein eL29 (60S rib · P47914 · RPL29 on Sugi Atlas →

3,647 patent compounds predicted against RPL29, 1,906 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL29 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES	PHASE3	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Quantification of GADD34 Expression in RA	nan	COMPLETED
Genetic and Blood Biomarkers in Neurological and Neuromuscular Diseases	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPL29 binder may also engage these)

Protein	Name	Similarity
Q8HXB8	—	1.000	Q8HXB8 →
Q95281	—	1.000	Q95281 →
Q58DW3	—	1.000	Q58DW3 →
P25886	—	1.000	P25886 →
G1TKB3	—	0.999	G1TKB3 →
Q9FF90	—	0.997	Q9FF90 →
O74175	—	0.997	O74175 →
P41125	—	0.996	P41125 →
Q90Z10	—	0.996	Q90Z10 →
RPL13	Large ribosomal subunit protein eL13	0.996	landscape →
Q876B2	—	0.996	Q876B2 →
P41129	—	0.996	P41129 →
P47915	—	0.996	P47915 →
P47963	—	0.995	P47963 →
Q54E20	—	0.994	Q54E20 →
A0A1D8PF57	—	0.993	A0A1D8PF57 →
P91128	—	0.993	P91128 →
Q6M0V9	—	0.992	Q6M0V9 →
B1YAF1	—	0.992	B1YAF1 →
O59931	—	0.992	O59931 →
P41123	—	0.992	P41123 →
Q9Z313	—	0.992	Q9Z313 →
P41126	—	0.992	P41126 →
O65059	—	0.992	O65059 →
Q9M7X7	—	0.992	Q9M7X7 →
P87558	—	0.991	P87558 →
B2JI62	—	0.991	B2JI62 →
A2SLF3	—	0.991	A2SLF3 →
A0KF25	—	0.991	A0KF25 →
Q962U1	—	0.991	Q962U1 →